BRIEF-Shattuck Labs - Announces Phase 1 Data For Sl-325

Shattuck

Shattuck

STTK

0.00

June 8 (Reuters) - Shattuck Labs Inc STTK.O:

  • SHATTUCK LABS - ANNOUNCES PHASE 1 DATA FOR SL-325

  • SHATTUCK LABS - ANTIDRUG ANTIBODIES TO SL-325 DETECTED IN 3.7% OF PARTICIPANTS

  • SHATTUCK LABS - SL-325 WELL TOLERATED WITH FAVORABLE SAFETY PROFILE

  • SHATTUCK LABS - NO EVIDENCE OF DR3 AGONISM OBSERVED

  • SHATTUCK LABS - PHASE 2B TRIAL OF SL-325 IN CROHN'S DISEASE TO START Q3 2026

  • SHATTUCK LABS - PHASE 1 TRIAL OF SL-846 EXPECTED TO INITIATE IN H1 2027

Source text: ID:nGNX6DMns3

Further company coverage: STTK.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.